HEADER TRANSFERASE 17-APR-23 8SIX TITLE STRUCTURE OF COMPOUND 13 BOUND TO THE CHK1 10-POINT MUTANT COMPND MOL_ID: 1; COMPND 2 MOLECULE: SERINE/THREONINE-PROTEIN KINASE CHK1; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: CHK1 CHECKPOINT HOMOLOG,CELL CYCLE CHECKPOINT KINASE, COMPND 5 CHECKPOINT KINASE-1; COMPND 6 EC: 2.7.11.1; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: CHEK1, CHK1; SOURCE 6 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 7108 KEYWDS LRRK2, PARKINSON'S, KINASE, TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR R.L.PALTE REVDAT 2 15-NOV-23 8SIX 1 JRNL REVDAT 1 01-NOV-23 8SIX 0 JRNL AUTH S.D.KATTAR,A.GULATI,K.A.MARGREY,M.H.KEYLOR,M.ARDOLINO,X.YAN, JRNL AUTH 2 R.JOHNSON,R.L.PALTE,S.E.MCMINN,L.NOGLE,J.SU,D.XIAO, JRNL AUTH 3 J.PIESVAUX,S.LEE,L.G.HEGDE,J.D.WOODHOUSE,R.FALTUS,L.Y.MOY, JRNL AUTH 4 T.XIONG,P.J.CIACCIO,K.PEARSON,M.PATEL,K.M.OTTE,C.E.G.LEYNS, JRNL AUTH 5 M.E.KENNEDY,D.J.BENNETT,E.F.DIMAURO,M.J.FELL,P.H.FULLER JRNL TITL DISCOVERY OF MK-1468: A POTENT, KINOME-SELECTIVE, JRNL TITL 2 BRAIN-PENETRANT AMIDOISOQUINOLINE LRRK2 INHIBITOR FOR THE JRNL TITL 3 POTENTIAL TREATMENT OF PARKINSON'S DISEASE. JRNL REF J.MED.CHEM. V. 66 14912 2023 JRNL REFN ISSN 0022-2623 JRNL PMID 37861679 JRNL DOI 10.1021/ACS.JMEDCHEM.3C01486 REMARK 2 REMARK 2 RESOLUTION. 1.55 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : AUTOBUSTER 2.11.7 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.55 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 54.34 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 61.6 REMARK 3 NUMBER OF REFLECTIONS : 28718 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.206 REMARK 3 FREE R VALUE : 0.238 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.850 REMARK 3 FREE R VALUE TEST SET COUNT : 1394 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 50 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.55 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.67 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 6.08 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 551 REMARK 3 BIN R VALUE (WORKING SET) : 0.2301 REMARK 3 BIN FREE R VALUE : 0.2452 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.17 REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2097 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 35 REMARK 3 SOLVENT ATOMS : 214 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 30.40 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.55710 REMARK 3 B22 (A**2) : -0.15090 REMARK 3 B33 (A**2) : -0.40620 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : -0.21670 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.26 REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : NULL REMARK 3 BOND ANGLES (DEGREES) : NULL REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL REMARK 3 IMPROPER ANGLES (DEGREES) : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 8SIX COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 17-APR-23. REMARK 100 THE DEPOSITION ID IS D_1000273799. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 18-JAN-20 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 6.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : CLSI REMARK 200 BEAMLINE : 08ID-1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.9795 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 6M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : AIMLESS REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 28718 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.550 REMARK 200 RESOLUTION RANGE LOW (A) : 54.344 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 92.7 REMARK 200 DATA REDUNDANCY : 4.100 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 9.6000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.55 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.73 REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 1.500 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: BUSTER REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 48.15 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.37 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 11% PEG 8000, 15-20% ETHYLENE GLYCOL, REMARK 280 0.1 M MES (PH 6.5), 5% 6-AMINOHEXANOIC ACID, VAPOR DIFFUSION, REMARK 280 SITTING DROP, TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 33.04500 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 1 REMARK 465 ALA A 2 REMARK 465 VAL A 3 REMARK 465 PRO A 4 REMARK 465 PHE A 5 REMARK 465 VAL A 6 REMARK 465 GLU A 7 REMARK 465 LYS A 43 REMARK 465 ARG A 44 REMARK 465 ALA A 45 REMARK 465 VAL A 46 REMARK 465 ASP A 47 REMARK 465 CYS A 48 REMARK 465 GLY A 272 REMARK 465 ALA A 273 REMARK 465 LYS A 274 REMARK 465 ARG A 275 REMARK 465 PRO A 276 REMARK 465 ARG A 277 REMARK 465 VAL A 278 REMARK 465 THR A 279 REMARK 465 SER A 280 REMARK 465 GLY A 281 REMARK 465 GLY A 282 REMARK 465 VAL A 283 REMARK 465 SER A 284 REMARK 465 GLU A 285 REMARK 465 SER A 286 REMARK 465 PRO A 287 REMARK 465 SER A 288 REMARK 465 GLY A 289 REMARK 465 HIS A 290 REMARK 465 HIS A 291 REMARK 465 HIS A 292 REMARK 465 HIS A 293 REMARK 465 HIS A 294 REMARK 465 HIS A 295 REMARK 465 HIS A 296 REMARK 465 HIS A 297 REMARK 480 REMARK 480 ZERO OCCUPANCY ATOM REMARK 480 THE FOLLOWING RESIDUES HAVE ATOMS MODELED WITH ZERO REMARK 480 OCCUPANCY. THE LOCATION AND PROPERTIES OF THESE ATOMS REMARK 480 MAY NOT BE RELIABLE. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 480 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 480 M RES C SSEQI ATOMS REMARK 480 GLU A 17 CB CG CD OE1 OE2 REMARK 480 TYR A 20 CB CG CD1 CD2 CE1 CE2 CZ REMARK 480 TYR A 20 OH REMARK 480 GLU A 50 CB CG CD OE1 OE2 REMARK 480 LYS A 53 CB CG CD CE NZ REMARK 480 ARG A 75 CG CD NE CZ NH1 NH2 REMARK 480 ASN A 78 CB CG OD1 ND2 REMARK 480 LYS A 271 CG CD CE NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 TRP A 9 -93.37 -118.71 REMARK 500 ASP A 10 117.19 106.20 REMARK 500 ASN A 63 88.11 -157.60 REMARK 500 ASP A 99 -7.30 67.90 REMARK 500 ASP A 130 42.13 -152.61 REMARK 500 ASP A 148 89.34 65.61 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A 614 DISTANCE = 6.20 ANGSTROMS DBREF 8SIX A 1 289 UNP O14757 CHK1_HUMAN 1 289 SEQADV 8SIX LEU A 59 UNP O14757 ASN 59 ENGINEERED MUTATION SEQADV 8SIX ILE A 68 UNP O14757 VAL 68 ENGINEERED MUTATION SEQADV 8SIX MET A 84 UNP O14757 LEU 84 ENGINEERED MUTATION SEQADV 8SIX LEU A 86 UNP O14757 TYR 86 ENGINEERED MUTATION SEQADV 8SIX ALA A 87 UNP O14757 CYS 87 ENGINEERED MUTATION SEQADV 8SIX SER A 91 UNP O14757 GLU 91 ENGINEERED MUTATION SEQADV 8SIX HIS A 134 UNP O14757 GLU 134 ENGINEERED MUTATION SEQADV 8SIX ALA A 147 UNP O14757 SER 147 ENGINEERED MUTATION SEQADV 8SIX TYR A 149 UNP O14757 PHE 149 ENGINEERED MUTATION SEQADV 8SIX SER A 150 UNP O14757 GLY 150 ENGINEERED MUTATION SEQADV 8SIX HIS A 290 UNP O14757 EXPRESSION TAG SEQADV 8SIX HIS A 291 UNP O14757 EXPRESSION TAG SEQADV 8SIX HIS A 292 UNP O14757 EXPRESSION TAG SEQADV 8SIX HIS A 293 UNP O14757 EXPRESSION TAG SEQADV 8SIX HIS A 294 UNP O14757 EXPRESSION TAG SEQADV 8SIX HIS A 295 UNP O14757 EXPRESSION TAG SEQADV 8SIX HIS A 296 UNP O14757 EXPRESSION TAG SEQADV 8SIX HIS A 297 UNP O14757 EXPRESSION TAG SEQRES 1 A 297 MET ALA VAL PRO PHE VAL GLU ASP TRP ASP LEU VAL GLN SEQRES 2 A 297 THR LEU GLY GLU GLY ALA TYR GLY GLU VAL GLN LEU ALA SEQRES 3 A 297 VAL ASN ARG VAL THR GLU GLU ALA VAL ALA VAL LYS ILE SEQRES 4 A 297 VAL ASP MET LYS ARG ALA VAL ASP CYS PRO GLU ASN ILE SEQRES 5 A 297 LYS LYS GLU ILE CYS ILE LEU LYS MET LEU ASN HIS GLU SEQRES 6 A 297 ASN VAL ILE LYS PHE TYR GLY HIS ARG ARG GLU GLY ASN SEQRES 7 A 297 ILE GLN TYR LEU PHE MET GLU LEU ALA SER GLY GLY SER SEQRES 8 A 297 LEU PHE ASP ARG ILE GLU PRO ASP ILE GLY MET PRO GLU SEQRES 9 A 297 PRO ASP ALA GLN ARG PHE PHE HIS GLN LEU MET ALA GLY SEQRES 10 A 297 VAL VAL TYR LEU HIS GLY ILE GLY ILE THR HIS ARG ASP SEQRES 11 A 297 ILE LYS PRO HIS ASN LEU LEU LEU ASP GLU ARG ASP ASN SEQRES 12 A 297 LEU LYS ILE ALA ASP TYR SER LEU ALA THR VAL PHE ARG SEQRES 13 A 297 TYR ASN ASN ARG GLU ARG LEU LEU ASN LYS MET CYS GLY SEQRES 14 A 297 THR LEU PRO TYR VAL ALA PRO GLU LEU LEU LYS ARG ARG SEQRES 15 A 297 GLU PHE HIS ALA GLU PRO VAL ASP VAL TRP SER CYS GLY SEQRES 16 A 297 ILE VAL LEU THR ALA MET LEU ALA GLY GLU LEU PRO TRP SEQRES 17 A 297 ASP GLN PRO SER ASP SER CYS GLN GLU TYR SER ASP TRP SEQRES 18 A 297 LYS GLU LYS LYS THR TYR LEU ASN PRO TRP LYS LYS ILE SEQRES 19 A 297 ASP SER ALA PRO LEU ALA LEU LEU HIS LYS ILE LEU VAL SEQRES 20 A 297 GLU ASN PRO SER ALA ARG ILE THR ILE PRO ASP ILE LYS SEQRES 21 A 297 LYS ASP ARG TRP TYR ASN LYS PRO LEU LYS LYS GLY ALA SEQRES 22 A 297 LYS ARG PRO ARG VAL THR SER GLY GLY VAL SER GLU SER SEQRES 23 A 297 PRO SER GLY HIS HIS HIS HIS HIS HIS HIS HIS HET ZXP A 301 35 HETNAM ZXP (1S)-N-(7-CHLORO-6-{4-[(3R,4R)-4-HYDROXY-3- HETNAM 2 ZXP METHYLOXOLAN-3-YL]PIPERAZIN-1-YL}ISOQUINOLIN-3-YL)-6- HETNAM 3 ZXP OXASPIRO[2.5]OCTANE-1-CARBOXAMIDE FORMUL 2 ZXP C26 H33 CL N4 O4 FORMUL 3 HOH *214(H2 O) HELIX 1 AA1 GLU A 50 LEU A 62 1 13 HELIX 2 AA2 PHE A 93 ILE A 96 5 4 HELIX 3 AA3 PRO A 103 ILE A 124 1 22 HELIX 4 AA4 LYS A 132 HIS A 134 5 3 HELIX 5 AA5 THR A 170 VAL A 174 5 5 HELIX 6 AA6 ALA A 175 ARG A 181 1 7 HELIX 7 AA7 HIS A 185 GLY A 204 1 20 HELIX 8 AA8 CYS A 215 GLU A 223 1 9 HELIX 9 AA9 PRO A 230 ILE A 234 5 5 HELIX 10 AB1 ASP A 235 LEU A 246 1 12 HELIX 11 AB2 THR A 255 LYS A 260 1 6 SHEET 1 AA1 5 LEU A 11 GLU A 17 0 SHEET 2 AA1 5 GLU A 22 VAL A 27 -1 O LEU A 25 N GLN A 13 SHEET 3 AA1 5 ALA A 34 ASP A 41 -1 O VAL A 35 N ALA A 26 SHEET 4 AA1 5 ILE A 79 MET A 84 -1 O GLN A 80 N VAL A 40 SHEET 5 AA1 5 PHE A 70 GLU A 76 -1 N GLY A 72 O PHE A 83 SHEET 1 AA2 3 GLY A 90 SER A 91 0 SHEET 2 AA2 3 LEU A 136 LEU A 138 -1 O LEU A 138 N GLY A 90 SHEET 3 AA2 3 LEU A 144 ILE A 146 -1 O LYS A 145 N LEU A 137 SHEET 1 AA3 2 ILE A 126 THR A 127 0 SHEET 2 AA3 2 THR A 153 VAL A 154 -1 O THR A 153 N THR A 127 SHEET 1 AA4 2 ARG A 156 TYR A 157 0 SHEET 2 AA4 2 ARG A 160 GLU A 161 -1 O ARG A 160 N TYR A 157 CISPEP 1 ASN A 229 PRO A 230 0 6.32 CRYST1 45.040 66.090 55.220 90.00 100.24 90.00 P 1 21 1 2 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.022202 0.000000 0.004011 0.00000 SCALE2 0.000000 0.015131 0.000000 0.00000 SCALE3 0.000000 0.000000 0.018403 0.00000